The Longevity Evidence Atlas
Every longevity intervention we know of, graded A to C by the strength of the human evidence behind it. Including the ones that failed, and the ones we work on ourselves.
The longevity field has a presentation problem. A compound with two large randomised human trials and a compound with one promising mouse study are described in the same register, sold at the same confidence, and priced similarly. The reader has no way to tell them apart without reading the primary literature, which is what the marketing depends on.
The Evidence Atlas is the working reference built to close that gap: seventy-three interventions across ten mechanistic categories, each carrying an explicit evidence tier, a plain-language summary of what is actually known, and a link to the trials underneath it. It is the same reference used internally to decide what the platform pursues — published rather than kept private, because a graded list is only credible if the grading is applied to one’s own programmes too.
Every gene therapy entry in the Atlas, including the targets this company’s own programmes are built on, is graded Level C — emerging evidence. Metformin, caloric restriction, cardiorespiratory fitness, resistance training, and sleep are graded Level A. A reference that ranked proprietary work highest would not be a reference.
The Evidence Atlas Web Application
Direct public access to our internal translational longevity database.
Every intervention carries a tier from A to C. The tier is stated in text on every card, shown as a three-segment confidence meter, and reinforced by a colour stripe — three cues rather than colour alone, so the grading survives a colour-blind reader and a black-and-white printout.
The Three-Tier Evidence Classification
Level A — Strong evidence
Supported by human randomised controlled trials or by large, consistent, long-term human cohort data with a plausible mechanism. These are interventions a physician can act on now. Most of them are unglamorous: exercise capacity, muscle mass, sleep, dietary pattern, and a small number of established drugs.
Level B — Moderate evidence
Supported by human data that is limited by size, duration, endpoint, or consistency — small trials, surrogate endpoints, or results awaiting replication. A rational basis to act exists; certainty does not.
Research Database
Seventy-three intervention records across ten mechanistic categories — genomics, senolytics, metabolic, NAD, epigenetic, lifestyle, stem cell, inflammation, microbiome, and hormonal. Each carries a stable identifier, an evidence tier, a summary of what the data shows, and the limits of that data.
Biomarkers & Healthspan Model
Tracks functional and biological aging markers against validated mortality tables, providing objective trajectory comparisons.
Who It Is For & What the Atlas Is Not
Physicians, researchers, patients, and institutional partners.
Physicians and researchers: A rapid reference for patients who ask about compounds they read about online. Every entry cites primary clinical papers. Patients and prospective patients: An antidote to longevity marketing. If an expensive supplement or treatment claims to reverse aging, check its tier here first. What the Atlas is not: It is not medical advice, it is not a personalized treatment plan, and it is not an endorsement of any compound listed within it.
Verbatim Principle
“A compelling mechanism is a reason to run a clinical trial, not a reason to treat patients.”
Inquire About Evidence-Based Longevity Consultations
Our clinical team assesses patients against objective functional and biomarker panels, advising on evidence-graded interventions.